{
    "organizations": [],
    "uuid": "9d16ff1bc91004c23219dee17b4293eee2407948",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-proqr-q4-loss-per-share-eur-039/brief-proqr-q4-loss-per-share-eur-0-39-idUSASB0C7YM",
    "ord_in_thread": 0,
    "title": "BRIEF-Proqr Q4 Loss Per Share ‍Eur 0.39",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Feb 28 (Reuters) - Proqr Therapeutics Nv:\n* PROQR ANNOUNCES RESULTS FOR THE FOURTH QUARTER AND FULL YEAR 2017 AND PROVIDES BUSINESS UPDATE\n* PROQR THERAPEUTICS NV - ‍CASH OF EUR 48.0 MILLION AT YEAR-END EXPECTED TO FUND OPERATIONS THROUGH ANTICIPATED CLINICAL DATA READOUTS IN 3 DIFFERENT PROGRAMS​\n* PROQR THERAPEUTICS NV QTRLY LOSS PER SHARE ‍ EUR 0.39 Source text for Eikon: Further company coverage:\n ",
    "published": "2018-02-28T20:12:00.000+02:00",
    "crawled": "2018-03-01T21:25:09.031+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "feb",
        "reuters",
        "proqr",
        "therapeutic",
        "nv",
        "proqr",
        "announces",
        "result",
        "fourth",
        "quarter",
        "full",
        "year",
        "provides",
        "business",
        "update",
        "proqr",
        "therapeutic",
        "nv",
        "eur",
        "million",
        "expected",
        "fund",
        "operation",
        "anticipated",
        "clinical",
        "data",
        "readout",
        "different",
        "proqr",
        "therapeutic",
        "nv",
        "qtrly",
        "loss",
        "per",
        "share",
        "eur",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}